Michael R. Savona, M.D.
- Beverly and George Rawlings Directorship
- Professor of Medicine (Hematology/Oncology)
- Director of Hematology Research
- Director, Hematology Early Therapeutics Program
Michael R. Savona, M.D.
- Beverly and George Rawlings Directorship
- Professor of Medicine (Hematology/Oncology)
- Director of Hematology Research
- Director, Hematology Early Therapeutics Program
michael.savona@vumc.org
Research Program
Departments/Affiliations
Provider Information
Profile
Education
- M.D., Wake Forest University School of Medicine, Winston-Salem, North Carolina
- B.A., Davidson College, Davidson, North Carolina
Research Emphasis
Research Description
Publications
- Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low Clinical Trial Accrual of Patients With Myelodysplastic Syndromes: Causes and Potential Solutions. Cancer [print-electronic]. 2018 Oct 10/5/2018; PMID: 30289970, DOI: 10.1002/cncr.31769, ISSN: 1097-0142.
- Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood [print-electronic]. 2018 Sep 9/21/2018; PMID: 30242087, PII: blood-2018-05-848473, DOI: 10.1182/blood-2018-05-848473, ISSN: 1528-0020.
- Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, Boyd KL, Strickland SA, Sensintaffar J, Hogdal LJ, Ayers GD, Olejniczak ET, Fesik SW, Savona MR. A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia. Cancer Discov [print-electronic]. 2018 Sep 9/5/2018; PMID: 30185627, PII: 2159-8290.CD-18-0140, DOI: 10.1158/2159-8290.CD-18-0140, ISSN: 2159-8290.
- Byrne M, Savani B, Savona MR. Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. Ther Adv Hematol. 2018 Sep; 9(9): 251-9. PMID: 30210754, PMCID: PMC6130097, PII: 10.1177_2040620718786437, DOI: 10.1177/2040620718786437, ISSN: 2040-6207.
- Savona MR, Kolibaba K, Conkling P, Kingsley EC, Becerra C, Morris JC, Rifkin RM, Laille E, Kellerman A, Ukrainskyj SM, Dong Q, Skikne BS. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am. J. Hematol [print-electronic]. 2018 Jul 7/17/2018; PMID: 30016552, DOI: 10.1002/ajh.25216, ISSN: 1096-8652.
- Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood [print-electronic]. 2018 Jun 6/14/2018; 131(24): 2661-9. PMID: 29724899, PII: blood-2017-12-818948, DOI: 10.1182/blood-2017-12-818948, ISSN: 1528-0020.
- Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clin. Cancer Res [print-electronic]. 2018 May 5/15/2018; 24(10): 2294-303. PMID: 29463550, PII: 1078-0432.CCR-17-2824, DOI: 10.1158/1078-0432.CCR-17-2824, ISSN: 1078-0432.
- Burris HA, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O'Connor OA. Umbralisib, a novel PI3Kd and casein kinase-1e inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol [print-electronic]. 2018 Apr; 19(4): 486-96. PMID: 29475723, PII: S1470-2045(18)30082-2, DOI: 10.1016/S1470-2045(18)30082-2, ISSN: 1474-5488.
- Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, Pawlikowska-Dobler I, Faessel HM, Dash AB, Sedarati F, Dezube BJ, Faller DV, Savona MR. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood [print-electronic]. 2018 Mar 3/29/2018; 131(13): 1415-24. PMID: 29348128, PMCID: PMC5909884, PII: blood-2017-09-805895, DOI: 10.1182/blood-2017-09-805895, ISSN: 1528-0020.
- Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leuk. Res [print-electronic]. 2018 Feb; 65: 67-73. PMID: 29310020, PMCID: PMC5856485, PII: S0145-2126(17)30617-3, DOI: 10.1016/j.leukres.2017.12.012, ISSN: 1873-5835.
- Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol [print-electronic]. 2018 Feb; 5(2): e63-e72. PMID: 29331635, PII: S2352-3026(18)30002-4, DOI: 10.1016/S2352-3026(18)30002-4, ISSN: 2352-3026.
